Printer Friendly

COMPANY INFORMATION
Akela Pharma Inc. 3700-1 place Ville-Marie Montréal, QC H3B 3P4 Tel: (512) 834-0449 Fax: (512) 834-2105 Contact Name Frédéric Dumais Industry Pharmaceuticals		Key Executives Gregory M. McKee, CEO Rudy Emmelot, v-p, fin. Develops therapeutics for pain using proprietary inhalation technology.
FP ADVISOR COVERAGE Akela Pharma Inc. • FP Corporate Analyzer • FP Directory of Directors • FP Corporate Surveys • FP Predecessor & Defunct • Ordering FP Products		TOP INDUSTRY PLAYERS Pharmaceuticals Company Name Revenue ($000s)  Biovail Corporation 807,909 Patheon Inc. 765,812 Cangene Corporation 238,751 Dragon Pharmaceutical, Inc. 162,127 Paladin Labs Inc. 82,744 (Links are to Snapshots.)
FINANCIAL RATIOS AS OF FEB 8/10 Listed Close 52-wk High 52-wk Low IAD Latest Dividend Yield 60-mo Beta TSX/AKL $0.14 $0.45 $0.13 n.a. n.a. n.a. 1.19 Avg 20-day Volume P/E 12-mo EPS EPS Date 1-yr Return 3-yr Return 5-yr Return Market Cap. (000s) 44,142 n.a. US$-0.95 Sept. 30/09 -15.62% -70.86% -51.83% $4,170
ANNUAL FINANCIALS Periods ended: 12m Dec. 31/08 12m Dec. 31/07 12m Dec. 31/06 US$000s US$000s $000s Operating revenue 14,774 12,632 29,448 Net income (25,989) (32,695) (227) Total assets 28,457 39,141 54,310 US$ US$ $ Earnings per share* (1.35) (2.79) nil % % % Return on equity (315.13) (144.35) (0.66)   * Common
TRAILING 12-MONTH VALUES Periods ended: Sept. 30/09 Sept. 30/08 US$000s US$000s Operating revenue 14,372 15,952 Net income (20,538) (21,267) US$ US$ Earnings per share (0.89) (1.48)

COMPANY NEWS

Results for 'Akela Pharma Inc.' from past 30 days: No hits. (Links are to articles.)